RxDoctor Payments DataLook up a doctor →

Corey Siegel, MD

Gastroenterology · Lebanon, NHNPI 1699798322

Payments from drug & device makers

$1,905,910in general payments, 2019–2025

Across 492 payments — averaging $3873.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$568K
  • Pfizer$396K
  • Bristol Myers Squibb$282K
  • AbbVie$231K
  • Janssen Research & Development, LLC$87K
  • Boston Scientific$75K
  • plus $267K from 14 others
$3,945in research payments, 2019–2025

Across 2 payments — averaging $1972.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • Pfizer$330

What the payments were for

  • Consulting fees$367,05461%
  • Speaking & faculty fees$150,14325%
  • Grants$50,0008%
  • Travel & lodging$32,6325%
  • Food & beverage$2,5680%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,905,910 in reported general payments places this provider in the 95th percentile of 91 gastroenterology providers in New Hampshire.

See all gastroenterology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$31,710
Medicare patients
170
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab122$3,129,330
Skyrizi On-BodyRisankizumab-Rzaa11$225,038
Humira(Cf) PenAdalimumab17$196,927
Mesalamine25$27,849
Mesalamine ErMesalamine13$9,082
Balsalazide Disodium15$7,586
LoperamideLoperamide Hcl20$1,700
Esomeprazole Magnesium22$1,493
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine26$995
Azathioprine13$819
Ondansetron OdtOndansetron34$658
Omeprazole21$436
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$307
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)12$152
Prednisone14$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$46,493$3,129,330122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 91 gastroenterology providers in New Hampshire.

Other gastroenterology in Lebanon

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →